To date, the Tom Zangas Memorial Lung Cancer Foundation through the generosity of many has provide more than $450,000 for lung cancer research. Here is an update on the grants and how your donations have helped fight this dreaded disease
How Your Donations Are Contributing to the Fight Against Lung Cancer
• A grant of $50,000 continues support of the Lung Cancer Research Foundation’s (LCRF’s) programs. This year LCRF has more than one grant track. One track focuses on understanding ways to improve clinical practices for effect management of side effects for non-small cell lung cancer patients receiving targeted therapies — drugs that interfere with specific molecules involved in the growth and spread of cancer. The other initiative focuses on the disparity in treatment and care of certain groups, such as low socio-economic status populations, those living in certain areas such as rural America, and racial/ethnic groups which are disproportionately affected by the disease.
• A second $30,000 grant to Dr. Abraham Chachoua, at Perlmutter Cancer Center at NYU Langone Health, who valiantly tried to extend Tom’s life, will be directed to lung cancer screening for underserved populations. Dr. Chachoua’s Perlmutter Cancer Center opened a facility at NYU Langone’s Brooklyn campus in the diverse neighborhood of Sunset Park. At that location, they are serving patients who are un or under insured. The Zangas Foundation’s funding will allow the center to offer screening to these patients.
• Previous grants to the LCRF funded a variety of research projects including prevention and screening for early detection; identification of new biomarkers and the development of targeted therapies; and development of next-generation chemotherapeutic agents. Many of these projects led to new avenues of research and important discoveries, which helped usher in the era of personalized medicine in lung cancer and continue to contribute to the development of the next generation of therapies.
• Previous grants to Dr. Abraham Chachoua funded research in developing novel ways to understand the impact of different treatment options. Last year’s contribution funded a program teaching new oncologists how to combine clinical skills, bedside manner and cutting-edge research to help lung cancer patients.